Project description
Non-invasive dermatological healthcare gets better
The skin is the largest organ of the body, protecting the internal organs from injury and bacterial infections. This is why dermatology is important in the diagnosis of many health conditions. The EU-funded CLEAN SLATE project will bring to market a new breakthrough technology set to dramatically improve non-invasive dermatological healthcare. According to studies, more than 100 million people are looking for a solution that focusses on exogenous and endogenous pigments. Current treatment offerings are ineffective, painful, damaging to skin tissue and lengthy. The new solution will overcome these barriers. The project will work on finalising the product development, performing tests in order to secure regulatory approval through clinical studies.
Objective
Founded by a world-leading physicist and a track-record technology entrepreneur, LightSense has developed and patented a breakthrough technology that dramatically improves non-invasive dermatological healthcare.
We plan to bring this technology to market through skincare clinics. We will initially offer aesthetic dermatology services focused on exogenous and endogenous pigments because (1) there is large and growing market, over 100 million people - and growing - are looking for a solution; (2) current treatment offerings are ineffective, painful, damaging to skin tissue, and
very lengthy; (3) our technology breakthrough positions us to offer a significantly better treatment experience; (4) we already have significant intellectual property protection that enables successful go to market.
With success in treating pigmentation disorders, we intend to quickly expand our offer, establishing industry-wide and academically-recognised solutions for many laser dermatology procedures.
This project focuses on finalising product development and testing, and gaining regulatory approval through clinical studies, and final commercialisation of the innovation.
Fields of science
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
N12 0BP London
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.